Search

Your search keyword '"Cantonetti, M."' showing total 277 results
Start Over Author "Cantonetti, M."
277 results on '"Cantonetti, M."'

51. EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY

Author

Gallamini, A., Fiore, F., Sorasio, R., Rambaldi, A., Patti, C., Stelitano, C., Viviani, S., DI RAIMONDO, Francesco, Feldman, T., Biggi, A., Rossi, A., Mistretta, A., Bonfante, V., Chiarenza, A., Cantonetti, M., Gavarotti, P., and Tarella, C.

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
2009

52. SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION

Author

Postorino, M, Pupo, L, Di Caprio, L, Campagna, S, Franceschini, L, Renzi, D, Rizzo, M, Gianni, L, Faccia, S, Cannarsa, R, Ales, M, Buccisano, F, Venditti, D, Cantonetti, M, and Amadori, S

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
2008

54. Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

Author

Zinzani, P. L., Martelli, Maurizio, Gianni, A. M., Devizzi, L., Federico, M., Pangalis, G., Michelis, J., Zucca, E., Cantonetti, M., Cortellazzo, S., Wotherspoon, A., Ferreri, A. J. M., Zaja, F., Lauria, F., DE RENZO, A., Liberati, M. A., Falini, B., Balzarotti, M., Calderoni, A., Zaccaria, A., Gentilini, P., Fattori, P. P., Pavone, E., Angelopoulou, M. K., Alinari, L., Brugiatelli, M., DI RENZO, N., Bonifazi, F., Pileri, S. A., and Cavalli, F.

Subjects
response rate, combined modality treatment, chemotherapy, PMLBCL, radiotherapy, PMLBCL, chemotherapy, radiotherapy, response rate, combined modality treatment
Published
2002

55. Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

Author

Pl, Zinzani, Martelli M, Bertini M, Am, Gianni, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Aj, Ferreri, Zaja F, Lauria F, De Renzo A, Ma, Liberati, Falini B, Balzarotti M, and Calderoni A

Subjects
PMLBCL, chemotherapy, radiotherapy, response rate, combined modality treatment
Published
2002

56. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Author

Benevolo, G, Stacchini, A, Spina, M, Ferreri, A, Arras, M, Bellio, L, Botto, B, Bulian, P, Cantonetti, M, Depaoli, L, Di Renzo, N, Di Rocco, A, Evangelista, A, Franceschetti, S, Godio, L, Mannelli, F, Pavone, V, Pioltelli, P, Vitolo, U, Pogliani, E, FERRERI, ALDO ANTONIO, POGLIANI, ENRICO MARIA, Benevolo, G, Stacchini, A, Spina, M, Ferreri, A, Arras, M, Bellio, L, Botto, B, Bulian, P, Cantonetti, M, Depaoli, L, Di Renzo, N, Di Rocco, A, Evangelista, A, Franceschetti, S, Godio, L, Mannelli, F, Pavone, V, Pioltelli, P, Vitolo, U, Pogliani, E, FERRERI, ALDO ANTONIO, and POGLIANI, ENRICO MARIA

Abstract

This prospective study compared diagnostic and prognostic value of conventional cytologic examination (CC) and flow cytometry (FCM) of baseline samples of cerebrospinal fluid in 174 patients with newly diagnosed aggressive NHL. FCM detected a neoplastic population in the CSF of 18 out of 174 patients (10%), CC only in 7 (4%) (p< 0.001); 11 patients (14%) were discordant (FCM+/CC-). At a median follow up of 46 months, there were 64 systemic progressions, 10 CNS relapses, including two patients with both systemic and CNS relapse. Two-year PFS and OS were significantly higher in patients with FCM-negative CSF (62% and 72%) compared with those FCMpositive CSF (39% and 50%) with a 2-year CNS relapse cumulative incidence of 3%(95%CI:0-7) vs.17%(95%CI:0-34)(p= 0.004), respectively. Discordant patients showed a significant increased risk of CNS progression at 2-year respect to both negative patients (HR 8.16, 95%CI:1.45-46). In conclusion, FCM positivity in CSF of patients with high-risk NHL is associated with a significantly higher CNS relapse risk and poorer outcome. Brain parenchyma was the commonest site of CNS failure, suggesting that the combination of i.v drugs with a higher CNS bioavailability and intrathecal chemotherapy is advisable to prevent CNS relapses in FCM+ patients.

Published
2012

57. S300: HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE REAL‐LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD)

Author

D'Agostino, M., Bringhen, S., Ria, R., Ciceri, F., Falcone, A. P., Michieli, M., Grasso, M., Pane, F., Quaresima, M., Cattel, F., Mirabile, M., Fioritoni, F., Petrucci, M. T., Cotugno, V., Capra, A., Pezzatti, S., Mosca Siez, M. L., Cantonetti, M., Margiotta Casaluci, G., and Bertazzoni, P.

Published
2022
Full Text
View/download PDF

59. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease

Author

Aglietta, M, Montemurro, F, Fagioli, F, Volta, C, Botto, B, Cantonetti, M, Racanelli, V, Teofili, L, Amadori, S, Castoldi, Gl, Dammacco, F, Levis, A, and Ferrara, R

Subjects
granulocyte-macrophage-colony stimulating factor, procarbazine, Hodgkin disease, hybrid mechlorethamine, vincristine, procarbazine, and prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine, myeloprotection, bleomycin, vinblastine, and prednisone, vincristine, doxorubicin, and dacarbazine
Published
2000

60. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Author

Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, Cortelazzo, S., Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, and Cortelazzo, S.

Abstract

Indolent primary cutaneous B cell lymphomas (PCBCL) generally have a good prognosis, but they often relapse leading in some cases to extracutaneous disease and therefore, to poor survival. We developed a prognostic model to improve the therapeutic approach to these lymphomas. Two hundred and seventeen patients with diagnosis of indolent PCBCL stage IE or IIE were assessed retrospectively. The prognostic model was built to fit a Cox proportional hazard model using all the covariates affecting progression-free survival (PFS) at p<0.1 in the univariate analysis, and the final model was selected based on the Bayes Information Criteria. Elevated serum lactate dehydrogenase, morphology of the lesion (nodule vs. other), and >2 lesions were independent predictors for PFS. To each prognostic factor was assigned a value of 1. Patients were then stratified to three risk groups: score 0 (28%), low risk; score 1 (55%), intermediate risk; score 2 and 3 (17%), high risk with a 5-year PFS of 91%, 64%, and 48%, respectively (p<0.001). The CLIPI is an easily applicable prognostic index and represents a promising tool for risk-adapted treatment strategies. However, it needs to be addressed in prospective clinical studies.

Published
2011

66. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph

Author

Zinzani, Pl, Martelli, M, Storti, S, Musso, M, Cantonetti, M, Leone, G, Cajozzo, A, Papa, G, Iannitto, E, Perrotti, A, Bendandi, M, Gherlinzoni, F, Gentilini, P, Rossi, G, Aitini, E, Mandelli, E, and Tura, S

Subjects
survival rate, Male, Heart Diseases, Lymphoma, Settore MED/06 - Oncologia Medica, cardiotoxicity, Non-Hodgkin, dexamethasone, antineoplastic activity, idarubicin, heart disease, doxorubicin, vincristine EMTREE medical terms: adult, vomiting MeSH: Adult, cancer combination chemotherapy, neurotoxicity, Antineoplastic Combined Chemotherapy Protocols, neutropenia, Humans, controlled study, human, Cyclophosphamide, controlled clinical trial, phase 3 clinical trial, nonhodgkin lymphoma, drug comparison, article, clinical trial, Middle Aged, alopecia, nausea, major clinical study, Survival Analysis, liver toxicity, EMTREE drug terms: antileukemic agent, cyclophosphamide, aged, cancer grading, female, male, mouth mucosa, mucosa inflammation, priority journal, randomized controlled trial, Aged, Doxorubicin, Female, Idarubicin, Lymphoma, Non-Hodgkin, Prednisone, Vincristine, Settore MED/15 - Malattie del Sangue
Published
1995

68. INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

Author

Tura, S, Baccarani, M, Zuffa, E, Russo, D, Zaccaria, A, Fiacchini, M, Testoni, N, Zamagni, M, Martinelli, G, Damiani, D, Michieli, M, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Alimena, G, Mandelli, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Majolino, I, Caronia, F, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Paolino, F, Resegotti, L, Ditucci, A, Broccia, G, Leoni, F, Ciolli, S, Luciano, L, Rotoli, B, Perricone, R, Cajozzo, A, Montuoro, A, Delaurenzi, A, Volpe, E, Demilio, A, Battista, R, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Lombardo, M, Torlontano, G, Landolfi, R, Leone, G, Delfini, C, Sparaventi, G, Papineschi, F, Spremolla, G, Risso, M, Marmont, A, Dini, D, Diprisco, U, Mangoni, L, Rizzoli, V, Girino, M, Ascari, E, Bodenizza, C, Carotenuto, M, Difrancesco, A, Quaglino, D, Nardelli, S, Ciccone, F, Miraglia, E, Debiase, R, Gallo, E, Pileri, A, Rambaldi, A, Barbui, T, Morandi, S, Bianchini, E, Derosa, C, Cimino, R, Ronca, F, Nobile, F, Cantonetti, M, Papa, G, Gallamini, A, Buffa, F, Musolino, C, Squadrito, G, Capaldi, A, Giovannelli, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Gentilini, I, Coser, P, Guglielmo, P, Cacciola, E, Pizzuti, M, Ricciuti, F, Fanin, R, Criscuolo, D, and Montefusco, E

Subjects
Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, BONE-MARROW TRANSPLANTATION, THERAPY, Settore MED/15 - Malattie del Sangue
Published
1994

70. Granulomatous mycosis fungoides responsive to gemcitabine

Author

Fargnoli, Mc, Peris, Ketty, Francesconi, F, Cantonetti, M, Cerroni, L, Chimenti, S., Peris, Ketty (ORCID:0000-0002-5237-0463), Fargnoli, Mc, Peris, Ketty, Francesconi, F, Cantonetti, M, Cerroni, L, Chimenti, S., and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

We report a 61-year-old woman with a 1-year-history of widespread erythematous scaly patches and plaques as well as red/purplish to brownish confluent plaques. Ulcerated lesions with a purulent, hemorrhagic exudate and sharp elevated borders were located on the lower extremities. Diagnosis of granulomatous mycosis fungoides was supported by histopathologic findings showing an inflammatory reaction with epithelioid and large giant cells associated with features characteristic of mycosis fungoides. Immunohistochemical studies showed a T-helper phenotype of neoplastic cells (CD3+, CD4+, CD45RO+) with expression of the cytotoxic protein TIA-1. Molecular analysis of TCRgamma gene demonstrated a monoclonal rearrangement in the lesional skin. After failure of conventional therapies, 6 cycles of gemcitabine treatment produced partial remission of cutaneous lesions and stable disease throughout a 12-month follow-up period, suggesting that gemcitabine is a promising chemotherapeutic agent for refractory mycosis fungoides.

Published
2002

71. EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986

Author

Tura, S, Fanin, R, Russo, D, Zuffa, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Delfini, C, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Pardini, S, Ambrosetti, A, Perona, G, Dini, D, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
RISK, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, CHRONIC GRANULOCYTIC-LEUKEMIA, CHEMOTHERAPY, IRRADIATION, RELAPSE, Settore MED/15 - Malattie del Sangue
Published
1993

72. PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION

Author

Tura, S, Russo, D, Fanin, R, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Silvestri, F, Virgolini, L, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Liberati, A, Tabilio, A, Martelli, M, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, and Ascari, E

Subjects
CHRONIC MYELOID LEUKEMIA, PROGNOSIS, INTERFERON Addresses, Settore MED/06 - Oncologia Medica, BONE MARROW TRANSPLANTATION, Settore MED/15 - Malattie del Sangue
Published
1993

73. KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML

Author

Gobbi, M, Tura, S, Russo, D, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Montefusco, E, Meloni, G, Mandelli, F, Zamagni, M, Testoni, N, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Bodenizza, C, Carotenuto, M, Rotondo, G, Ambrosetti, A, Perona, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Morra, E, Bernasconi, C, Rambaldi, A, Barbui, T, Ronco, F, Nobile, F, Leoni, P, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Gentilini, I, Coser, P, Dini, D, Diprisco, U, Papineschi, F, Spremolla, G, Liberati, A, Grignani, G, Tabilio, A, Martelli, M, Pardini, S, Longinotti, M, Mangoni, L, Rizzoli, V, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Leoni, F, Ciolli, S, Cantonetti, M, Papa, G, Landolfi, R, Leone, G, Gallo, E, Pileri, A, Zagonel, V, Pinto, A, Volpe, E, Difrancesco, A, Quaglino, D, Avanzini, P, Gobbi, F, Paolino, F, Resegotti, L, Saglio, G, Camaschella, C, Mazza, U, Pinotti, G, Venco, G, Capucci, A, Izzi, T, Morandi, S, Bianchini, E, Scapoli, G, Monaco, M, Pizzuti, M, Ricciuti, F, Capaldi, A, and Giovannelli, E

Subjects
INTERFERON, AUTOLOGOUS BMT, Settore MED/06 - Oncologia Medica, KARYOTYPIC CONVERSION, Settore MED/15 - Malattie del Sangue, PH+CML
Published
1993

74. TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE

Author

Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Ciccone, F, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Saglio, G, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
CHRONIC MYELOID LEUKEMIA, PHILADELPHIA CHROMOSOME, INTERFERON AUTOLOGOUS BONE MARROW TRANSPLANT, Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
1993

76. Menstrual function in patients undergoing chemotherapy for Hodgkin's disease

Author

Ticconi, C, Giacomello, F, De Santis, L, Abruzzese, E, Pasqua, C, and Cantonetti, M

Subjects
procarbazine, clinical article, bleomycin, chlormethine, Settore MED/06 - Oncologia Medica, EMTREE drug terms: antineoplastic agent, article, oral drug administration, dacarbazine, doxorubicin, vincristine EMTREE medical terms: adult, cancer chemotherapy, hodgkin disease, intravenous drug administration, female, vinblastine, prednisone, human, menstruation, Settore MED/15 - Malattie del Sangue
Published
1992

77. Biological and clinical advances in multiple myeloma: A review

Author

Coppetelli, U, Avvisati, G, Tribalto, M, Cantonetti, M, La Verde, G, Petrucci, T, Stasi, R, and Papa, G

Subjects
EMTREE drug terms: alpha interferon, carmustine, Settore MED/06 - Oncologia Medica, cyclophosphamide, doxorubicin, melphalan, prednisone, semustine, vincristine EMTREE medical terms: human, multiple myeloma, oral drug administration, review MeSH: Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, English Abstract, Human, Interferon-alpha, Karyotyping, Melphalan, Multiple Myeloma, Phenotype, Prednisone, Prospective Studies, Randomized Controlled Trials, Settore MED/15 - Malattie del Sangue
Published
1992

78. P086 Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphopma: unicentric experience

Author

Postorino, M., primary, Cantonetti, M., additional, Franceschini, L., additional, De Angelis, G., additional, Cudillo, L., additional, Cerretti, R., additional, Giannì, L., additional, Rizzo, M., additional, Lombardo, G., additional, Didona, B., additional, Ditto, C., additional, Di Caprio, L., additional, Faccia, S., additional, Pupo, L., additional, Renzi, W., additional, and Arcese, D., additional

Published
2007
Full Text
View/download PDF

79. CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE

Author

Tura, S, Russo, D, Zuffa, E, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Lucarelli, G, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Longinotti, M, Ambrosetti, A, Perona, G, Dini, D, Diprisco, U, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
MARROW TRANSPLANTATION, CHRONIC MYELOCYTIC-LEUKEMIA, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, DURATION, SURVIVAL, CHRONIC PHASE, CHRONIC GRANULOCYTIC-LEUKEMIA, MULTIVARIATE-ANALYSIS, BCR BREAKPOINT, DIAGNOSIS, Settore MED/15 - Malattie del Sangue
Published
1991

81. Short term treatment withEscheria coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease

Author

Aglietta, M., primary, Montemurro, F., additional, Fagioli, F., additional, Volta, C., additional, Botto, B., additional, Cantonetti, M., additional, Racanelli, V., additional, Teofili, L., additional, Ferrara, R., additional, Amadori, S., additional, Castoldi, G. L., additional, Dammacco, F., additional, and Levis, A., additional

Published
2000
Full Text
View/download PDF

82. MACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's Lymphomas

Author

Mazza, P., primary, Zinzani, P. L., additional, Martelli, M., additional, Fiacchini, M., additional, Bocchia, M., additional, Pileri, S., additional, Falini, B., additional, Martelli, M. F., additional, Amadori, S., additional, Papa, G., additional, Cantonetti, M., additional, Lucarelli, G., additional, Moretti, L., additional, Calabresi, F., additional, Ruggeri, E., additional, Gherlinzoni, F., additional, Bendandi, M., additional, Guglielmi, C., additional, Burgio, V., additional, Dammacco, F., additional, Lauta, V. M., additional, Liberati, A. M., additional, Mandelli, F., additional, and Tura, S., additional

Published
1995
Full Text
View/download PDF

83. Phase III Comparative Trial Uisng CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's Lymphoma

Author

Zinzani, P. L., primary, Martelli, M., additional, Storti, S., additional, Musso, M., additional, Cantonetti, M., additional, Leone, G., additional, Cajozzo, A., additional, Papa, G., additional, Iannitto, E., additional, Perrotti, A., additional, Bendandi, M., additional, Gherlinzoni, F., additional, Gentilini, P., additional, Rossi, G., additional, Aitini, E., additional, Mandelli, F., additional, and Tura, S., additional

Published
1995
Full Text
View/download PDF

85. Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions.

Author

Masala S, Volpi T, Fucci FP, Cantonetti M, Postorino M, Simonetti G, Masala, Salvatore, Volpi, Tommaso, Fucci, Francesco P M, Cantonetti, Maria, Postorino, Massimiliano, and Simonetti, Giovanni

Abstract

Purpose: The aim of our study was to assess the efficacy and safety of percutaneous osteoplasty (PO), a technical extension of percutaneous vertebroplasty, in the treatment of extraspinal bone lesions from multiple myeloma causing pain resistant to NSAID therapy or treated with opioids.Methods: Between March 2006 and January 2009, 39 patients (22 female), median age 64 years (range 48-88 years) with diagnosis of multiple myeloma, were treated with percutaneous osteoplasty for painful extraspinal bone lesions resistant to NSAID therapy or treated with opioids.Results: Technical success was achieved in all cases. Mean visual analog pain score (VAS) scores dropped from 8.4 ± 1 (range 6-10; pretreatment) to 2.1 ± 1.7 (range 0-7; 24-h posttreatment). Pain completely disappeared in six (15%) patients. Administration of analgesics was suspended in 16 (41%) patients whereas in 17 (43.5%) patients previously treated with opioids, residual pain was controlled by NSAIDs. In six (15%) patients, narcotics administration was continued due to the persistence of pain. All patients completed an at least 6-month follow-up with a median long-term VAS score of 2.4 ± 2.1 (range 0-9). In five (13%) patients, pain remission was complete, with no recurrence at 18 months from treatment.Conclusion: Our study suggests that PO may be feasible, effective, and safe in the treatment of conventional therapy-resistant extraspinal painful multiple myeloma lesions providing long-lasting pain relief with occasional tumor control and a significant reduction in the assumption of analgesic drugs. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

88. Short term treatment with <TOGGLE>Escheria coli</TOGGLE> recombinant human granulocyte-macrophage–colony stimulating factor prior to chemotherapy for Hodgkin disease

Author

Aglietta, M., Montemurro, F., Fagioli, F., Volta, C., Botto, B., Cantonetti, M., Racanelli, V., Teofili, L., Ferrara, R., Amadori, S., Castoldi, G. L., Dammacco, F., and Levis, A.

Abstract

Granulocyte-macrophage–colony stimulating factor (GM-CSF) administration stimulates the proliferation of hemopoietic progenitors. Shortly (48–96 hours) after its discontinuation, feedback phenomena occur and the progenitor proliferation rate drops below baseline levels. As the quiescence of hyperplastic bone marrow suggests that hemopoietic cells may be refractory to the toxic effects of cytostatic drugs, the decision was made to test the hypothesis that GM-CSF given before chemotherapy may be myeloprotective. Fifty-six patients with newly diagnosed Stage II–IV Hodgkin disease, ages 18–77 years, were randomized to receive GM-CSF (5 μg/kg subcutaneously) or placebo from Day 7 to Day 4 before each chemotherapy administration (6 cycles of a hybrid of mechlorethamine, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine). The treatment was considered a success if the delivery rate of chemotherapy was >90% after 3 cycles and >80% after 6 cycles. Thirty patients received GM-CSF and 26 placebo. The dose intensity (85.2% vs. 79.6%) and the overall success in terms of delivery rate (56.7% vs. 50%) were higher in the GM-CSF group, although these differences were not statistically significant. The neutrophil nadirs were higher in the GM-CSF group during the first three cycles and subsequently similar in both groups. No significant differences in terms of myelotoxicity or drug delivery were observed between the two treatment arms. Although the myeloprotective effect of the prechemotherapy administration of GM-CSF seems to be minimal, the data indicate a safe timing between GM-CSF discontinuation and further chemotherapy. Because cumulative myelotoxicity has been observed with other growth factors, given in the interval between the chemotherapy cycles, this may be relevant to the planning of rapid cycling. Cancer 2000;88:454–60. © 2000 American Cancer Society.

Published
2000
Full Text
View/download PDF

89. Citations and Clinicians' Notes: Non-Hodgkin's Lymphoma.

Author

Martelli, M, Gherlinzoni, F, De Renzo, A, Zinzani, PL, De Vivo, A, Cantonetti, M, Falini, B, Storti, S, Meloni, G, and Rizzo, M

Subjects
HODGKIN'S disease, LYMPHOMAS, STEM cell transplantation, DRUG therapy, IMMUNOTHERAPY
Abstract

Presents information on non-Hodgkin's lymphoma from citations and notes of clinicians. Discussion on early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma; Significant diffuse component for inferior survival in grade 3 follicular lymphoma; Insight on the safety of yttrium-90 Ibritumomab Tiuxetan radio immunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma.

Published
2003

91. Prognosi e terapia del mieloma multiplo

Author

Pileri, A., Boccadoro, M., Avvisati, G., Barbui, T., Cantonetti, M., Carotenuto, M., Comotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Grignani, F., Lauta, V. M., Liberati, Anna Marina, Neretto, G., Marmont, A., Petrucci, M. T., Resegotti, L., Tribalto, M., and Mandelli, F.

Published
1989

93. Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy

Author

Zinzani, P. L., Martelli, M., Magagnoli, M., Zaccaria, A., Ronconi, F., Cantonetti, M., Bocchia, M., Marra, R., Gobbi, M., Brunangelo FALINI, Gherlinzoni, F., Moretti, L., Renzo, A., Mazza, P., Pavone, E., Sabattini, E., Amendola, A., Bendandi, M., Pileri, S. A., Mandelli, F., and Tura, S.

Subjects
Male, Lymphoma, Settore MED/06 - Oncologia Medica, Leucovorin, vincristine EMTREE medical terms: adult, Antineoplastic Combined Chemotherapy Protocols, anaplastic carcinoma, Tomography, Ki-1, clinical article, large cell lymphoma, Remission Induction, article, Mediastinum, clinical trial, Middle Aged, Combined Modality Therapy, Hodgkin Disease, Large-Cell, Dacarbazine, aged, female, Treatment Outcome, priority journal, Vincristine, Lymphoma, Large-Cell, Anaplastic, EMTREE drug terms:bleomycin, cyclophosphamide, dacarbazine, doxorubicin, folinic acid, methotrexate, prednisone, vinblastine, antineoplastic activity, cancer combination chemotherapy, cancer radiotherapy, controlled study, human, human tissue, male, randomized controlled trial, treatment outcome MeSH:Adolescent, Adult, Bleomycin, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Follow-Up Studies, Humans, Lymphoma, Large-Cell, Ki-1, Methotrexate, Prednisone, Survival Analysis, Tomography, Emission-Computed, Single-Photon, Vinblastine, Adolescent, adult, cd30+/ki-1+, classification, clinical-features, disease, f-machop regimen, reed-sternberg cells, variant, Emission-Computed, Settore MED/15 - Malattie del Sangue, Single-Photon
Abstract

During the last few years, morphological, immunohistochemical, and genetic findings have placed anaplastic large cell lymphoma (ALCL) as a distinct clinicopathologic entity, and several reports have focused on the existence of different subtypes of the tumor. Particular attention has been paid to the ALCL-Hodgkin's-like (HL) subtype, which seems to be on the border between Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL). From September 1994 to July 1997, during the course of an Italian multicentric trial, 40 ALCL-HLs were randomized to receive as front-line chemotherapy MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin-a third-generation HG-NHL regimen) or ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine-a scheme specific for HD). All patients with bulky disease in the mediastinum at diagnosis underwent local radiotherapy after the chemotherapeutic program. Complete response (CR) was achieved in 17 of the 19 (90%) patients who were treated with MACOP-B, and in 19 of the 21 (91%) patients who were administered ABVD. The probability of relapse-free survival, projected at 32 months, was 94% for the MACOP-B subset and 91% for the ABVD subset. The majority of patients with mediastinal bulky disease obtained CR (evaluated with 67Ga single photon emission computed tomography [SPECT]) after their radiotherapy. The present study suggests that ALCL-HL, in line with its borderline status, responds in an equivalent way to third-generation chemotherapy for HG-NHL and to conventional HD treatment in terms of both CR and relapse-free survival rates. However, as to the latter, a longer follow-up period may be needed before stating the absolute equivalence of the two regimens used.

94. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease

Author

Anselmo, A. P., Cavalieri, E., Meloni, G., Alimena, G., Cantonetti, M., Enrici, R. M., Tosti, M. E., Osti, M. F., Valentina Gianfelici, and Mandelli, F.

Subjects
Adult, Male, Salvage Therapy, Settore MED/06 - Oncologia Medica, salvage chemotherapy, resistant hodgkin's disease, autologous, mortality, Hodgkin Disease, Survival Analysis, Transplantation, Autologous, mortality/therapy, administration /&/ dosage, adult, antineoplastic combined chemotherapy protocols, autotransplant, female, follow-up studies, hodgkin disease, humans, iev regimen, male, recurrence, retrospective studies, salvage therapy, stem cell transplantation, survival analysis, transplantation, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Settore MED/15 - Malattie del Sangue, Follow-Up Studies, Retrospective Studies, Stem Cell Transplantation
Abstract

Patients affected by Hodgkin's disease (HD) resistant to induction therapy or who have a brief duration of first remission have a poor outcome.We retrospectively reviewed the clinical data of 28 patients affected by Hodgkin's disease who relapsed 6 to 24 months from completion of treatment (14 patients) or who were refractory to first-line therapy or relapsed very early (14 patients). All the 28 patients were treated with salvage chemotherapy plus a conditioning regimen followed by peripheral blood stem cell transplant (PBCST) or autologous bone marrow transplant (ABMT).At a median follow-up of 35.5 months (range 14-119), of the 14 patients responding to first-line therapy but who relapsed6 months off therapy, 10 (72%) are alive, well and in complete remission (CR), 2 (14%) are alive with disease at 39 and 83 months from transplant, and 2 (14%) died 26 and 63 months after their transplant from acute myeloid leukemia and HD, respectively. At a median follow-up of 39 months, the overall survival (OS) is 68% and the event-free survival (EFS) is 56%. At a median follow-up of 30 months (1-98), of the 14 patients refractory to first-line therapy or who relapsed very early, 9 (64%) are alive in CR, 1 (7%) is alive with disease and 4 (29%) have died of their disease (3 patients) or myelodysplastic syndrome (1 patient). The OS is 58% and the EFS is 52%. There are no statistically significant differences in terms of OS and EFS between the two groups of patients.Our study shows that salvage chemotherapy followed by a conditioning regimen and autotransplant is an effective, feasible and well-tolerated scheme of therapy not only for patients with HD who relapse after first-line treatment, but also for those resistant to first-line treatment.

95. Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients

Author

Zinzani, P. L., Martelli, M., Bertini, M., Gianni, A. M., Devizzi, L., Massimo FEDERICO, Pangalis, G., Michels, J., Zucca, E., Cantonetti, M., Cortelazzo, S., Wotherspoon, A., Ferreri, A. J. M., Zaja, F., Lauria, F., Renzo, A., Liberati, M. A., Falini, B., Balzarotti, M., Calderoni, A., Zaccaria, A., Gentilini, P., Fattori, P. P., Pavone, E., Angelopoulou, M. K., Alinari, L., Brugiatelli, M., Di Renzo, N., Bonifazi, F., Pileri, S. A., and Cavalli, F.

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue

96. Therapy of multiple myeloma

Author

Boccadoro, M., Avvisati, G., Cantonetti, M., Cavo-Comotti, B. M., Frieri, R., Gallamini, A., Gallone, G., Lauta, V. M., Liberati, M., Marmont, F., Marceno, R., Pellegrino Musto, Neretto, G., Petrucci, M. T., Tribalto, M., and Pileri, A.

99. BONE MARROW INVOLVEMENT AT DIAGNOSIS IS A POOR PROGNOSTIC FACTOR IN YOUNG PATIENTS WITH UNTREATED HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: SUB-ANALYSIS OF THE PHASE III RANDOMIZED FIL-DLCL04 TRIAL

Author

Chiappella, A., Russo, E., Brusamolino, E., Angelucci, E., Rossi, G., Carella, A. M., Evangelista, A., Stelitano, C., Balzarotti, M., Gotti, M., Merli, F., Gaidano, G., Pavone, V., Rigacci, L., Zaja, F., Rusconi, C., Renzo, A., Pinotti, G., Michele Spina, Pizzuti, M., Cantonetti, M., Specchia, G., Pregno, P., Pecoraro, C., Tucci, A., Cabras, M. G., Salvi, F., Martelli, M., and Vitolo, U.

Catalog

Books, media, physical & digital resources
See catalog results